Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma

Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with EGFR over-expression also express a constitutively active ligand independent EGFR variant III (EGFRvIII). While current treatments emphasize surgery followed by radiation and chemotherapy with Temozolomide (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Velpula, Kiran K., Guda, Maheedhara R., Sahu, Kamlesh, Tuszynski, Jack, Asuthkar, Swapna, Bach, Sarah E., Lathia, Justin D., Tsung, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482605/
https://www.ncbi.nlm.nih.gov/pubmed/28410193
http://dx.doi.org/10.18632/oncotarget.16767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482605/
https://www.ncbi.nlm.nih.gov/pubmed/28410193
http://dx.doi.org/10.18632/oncotarget.16767

Ejemplares similares